Intratympanic steroid injection versus hyperbaric oxygen therapy in refractory sudden sensorineural hearing loss: a meta-analysis. | Canada Hyperbarics Skip to main content
Meta-Analysis European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - 2022

Intratympanic steroid injection versus hyperbaric oxygen therapy in refractory sudden sensorineural hearing loss: a meta-analysis.

Kuo TC, Chao WC, Yang CH, Tsai MS, Tsai YT, Lee YC — European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - , 2022

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers conducted a meta-analysis to compare the effectiveness of intratympanic steroid injections versus hyperbaric oxygen therapy as salvage treatments for refractory sudden sensorineural hearing loss.

What They Found

Analyzing data from 314 subjects across 3 observational studies and 1 randomized controlled trial, the researchers found no significant differences in mean post-treatment hearing gain between intratympanic steroid and hyperbaric oxygen therapy groups. Improvements in word discrimination and hearing gain across various frequencies (250-8000 Hz) were also comparable between the two salvage treatments.

What This Means for Canadian Patients

Canadian patients with refractory sudden sensorineural hearing loss who have not responded to initial treatment may consider either intratympanic steroid injections or hyperbaric oxygen therapy as salvage options. The choice between these two treatments could depend on factors like availability, patient preference, and potential side effects.

Canadian Relevance

This study has no direct Canadian connection.

Study Limitations

A limitation of this meta-analysis is the potential for spontaneous recovery to bias treatment outcomes, and it included a limited number of studies and subjects.

Was this summary helpful?

Study Details

Study Type Meta-Analysis
Category Sudden Hearing Loss
Source Pubmed
PubMed ID 33751195
Year Published 2022
Journal European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology -
MeSH Terms Dexamethasone; Glucocorticoids; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Humans; Hyperbaric Oxygenation; Injection, Intratympanic; Observational Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Steroids; Treatment Outcome

Cite This Study

Share

Find a Canadian Clinic Treating Sudden Hearing Loss

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.